Open an account

Enlivex

ENLV · NASDAQ

$0.2237−$0.0001 (−0.04%)TodayMarket closed ·
Prev close $0.2238

ENLV analyst rating

BuyConsensus of 2 analysts over the last 12 months. 50% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold1
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $81.60 (+36377.4% upside)

Low
$80.80
Now
$0.2237
High
$84.00

Upgrades and downgrades

The latest rating actions, newest first

ENLV analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 3, 2026MaintainsBuy
HC Wainwright & Co.Apr 7, 2026MaintainsBuy
HC Wainwright & Co.Jan 12, 2026MaintainsBuy
D. Boral CapitalNov 24, 2025DowngradeBuy → Hold
D. Boral CapitalOct 29, 2025MaintainsBuy

The case for and against

Updated Jun 30, 2026

Bull case

Enlivex is a clinical-stage immunotherapy company with a robust and diversified portfolio, including Allocetra, a potential treatment for osteoarthritis and sepsis, and a RAIN token treasury which could have significant value as the prediction market segment continues to grow rapidly. The recent announcement of regulatory clearance for Allocetra's Phase 2b clinical trial is a promising development, and Enlivex's innovative digital asset treasury strategy has the potential to add significant value in the future. While there are risks to achieving the indicated price target, including factors related to clinical studies and market penetration, Enlivex's strong portfolio and strategic initiatives make it an attractive investment opportunity.

Bear case

Enlivex is a clinical stage immunotherapy company with a negative outlook, as their current market valuation does not take into account their potential future value driver, an option to purchase up to $918M worth of RAIN tokens at a per-token price of $0.0033. Even with a discounted cash flow-based valuation of $4.66B, or a price target of $13 per share, there are significant risks to achieving this target including adverse results from clinical studies, challenges in market penetration, and potential dilution risk. Additionally, the volatility and liquidity challenges of RAIN tokens could also impact Enlivex's financials in the near to medium term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.